Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)

Talha Badar, MBBS,FCPS, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Sherry R. Pierce, RN, BS, Naval Daver, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3186.

https://doi.org/10.1182/blood.V124.21.3186.3186

Published: 2014

Journal Articles

Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype

Marcos R Estecio, PhD, Sirisha Maddipoti, MD, Courtney D. DiNardo, MD, Hui Yang, William S Stevenson, MBBS, PhD, Carlos E. Bueso-Ramos, MD PhD, Sherry R. Pierce, RN, BS, Yue Wei, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 3548.

https://doi.org/10.1182/blood.V124.21.3548.3548

Published: 2014

Journal Articles

Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience

Koji Sasaki, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Sherry R. Pierce, RN, BS, Naveen Pemmaraju, MD, Susan O'Brien, MD, Farhad Ravandi, MD

Blood (2014) 124 (21): 2273.

https://doi.org/10.1182/blood.V124.21.2273.2273

Published: 2014

Journal Articles

Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups

Koji Sasaki, Sara S. Strom, PhD, Susan O'Brien, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Sherry R. Pierce, RN, BS, Hagop M. Kantarjian, MD, Jorge E. Cortes

Blood (2014) 124 (21): 1801.

https://doi.org/10.1182/blood.V124.21.1801.1801

Published: 2014

Journal Articles

Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia

Pramod Pinnamaneni, MD, Jeffrey L. Jorgensen, MD PhD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Sherry R. Pierce, RN, BS, Mark Brandt, Sa A. Wang, MD, Sergej Konoplev, MD PhD, Marina Konopleva, MD PhD, Steven M. Kornblau, MD, Tapan Kadia, MD, Courtney D. DiNardo, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Zeev Estrov, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, Farhad Ravandi, MD

Blood (2014) 124 (21): 1015.

https://doi.org/10.1182/blood.V124.21.1015.1015

Published: 2014

Journal Articles

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Young Kwang Chae, MD, MPH, Hagop M Kantarjian, MD, Muhamed Baljevic, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Susan O'Brien, MD, Carlos G. Romo, M.D., Sherry R. Pierce, RN, BS, Elias Jabbour, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2724.

https://doi.org/10.1182/blood.V122.21.2724.2724

Published: 2013

Journal Articles

Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy

Shilpan S. Shah, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MBBS, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD, Elias Jabbour, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MBBS, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2654.

https://doi.org/10.1182/blood.V122.21.2654.2654

Published: 2013

Journal Articles

Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age

Naval G. Daver, MD, Kiran Naqvi, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Farhad Ravandi, MD, Aziz Nazha, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Mark Brandt, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Sherry R. Pierce, RN, BS, Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 1530.

https://doi.org/10.1182/blood.V122.21.1530.1530

Published: 2013

Journal Articles

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ghayathri Jeyakumar, MD, Hagop M. Kantarjian, MD, Kendra L. Sweet, MD, Cecilia Y Arana Yi, MD, Nitin Jain, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Brenda Walker, RN, Sherry R. Pierce, RN, BS, Tapan M. Kadia, MD, Farhad Ravandi, MD, Javier Pinilla, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4044.

https://doi.org/10.1182/blood.V122.21.4044.4044

Published: 2013

Journal Articles

Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System

Rozovski Uri, MD, Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Sherry R. Pierce, RN, BS, Kantarjian Hagop, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 3883.

https://doi.org/10.1182/blood.V122.21.3883.3883

Published: 2013

Journal Articles

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

Aziz Nazha, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Stefan H. Faderl, MD, Jing Ning, Wei Qiao, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry R. Pierce, RN, BS, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2788.

https://doi.org/10.1182/blood.V122.21.2788.2788

Published: 2013

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach

Courtney D. DiNardo, MD, Naval G. Daver, MD, Nitin Jain, MD, Naveen Pemmaraju, MD, Carlos E. Bueso-Ramos, MD, PhD, Cheng Yin, Sherry R. Pierce, RN, BS, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 2825.

https://doi.org/10.1182/blood.V122.21.2825.2825

Published: 2013

Journal Articles

Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Roland B Walter, MD, PhD, Megan Othus, PhD, Alan K. Burnett, MD, Bob Löwenberg, MD, PhD, Hagop M. Kantarjian, MD, Gert J. Ossenkoppele, MD PhD, Robert K. Hills, MA, MSc, DPhil, Farhad Ravandi, MD, Anna Evans, PhD, Sherry R. Pierce, RN, BS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 64.

https://doi.org/10.1182/blood.V122.21.64.64

Published: 2013

Journal Articles

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Roland B. Walter, Megan Othus, Alan K. Burnett, Bob Löwenberg, Hagop M. Kantarjian, Gert J. Ossenkoppele, Robert K. Hills, Kees G. M. van Montfort, Farhad Ravandi, Anna Evans, Sherry R. Pierce, Frederick R. Appelbaum, Elihu H. Estey

Blood (2013) 121 (13): 2424–2431.

https://doi.org/10.1182/blood-2012-10-462440

Published: 2013

Includes: Supplemental data

NARROW

Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)

Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype

Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience

Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups

Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy

Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach

Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only